3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
CNS
1
Conditions
Glioblastoma
264
Glioma
109
Brain Neoplasms
104
Gliosarcoma
85
Central Nervous System Neoplasms
64
Astrocytoma
61
Melanoma
46
Oligodendroglioma
44
Neuroblastoma
28
Recurrence
22
Neoplasm Metastasis
18
Neoplasms
16
Medulloblastoma
16
Ependymoma
16
Sarcoma, Ewing
13
Lymphoma
13
Sarcoma
12
Rhabdomyosarcoma
11
Neuroendocrine Tumors
11
Lung Neoplasms
11
Diffuse Intrinsic Pontine Glioma
10
Small Cell Lung Carcinoma
9
Neuroectodermal Tumors, Primitive
7
Colorectal Neoplasms
7
Unspecified Adult Solid Tumor, Protocol Specific
6
Osteosarcoma
6
Pinealoma
5
Optic Nerve Glioma
5
Choroid Plexus Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Interventions
lenvatinib
2
temsirolimus
1
penpulimab
1
cabozantinib
1
anlotinib
1
Vinorelbine
1
Temozolomide
1
Sirolimus
1
Restraint, Physical
1
Everolimus
1
Absorptiometry, Photon
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Paraganglioma, Extra-Adrenal
×
Temozolomide
×
Clear all
NCT05858177
2023-05-15
MPPGL
Peking Union Medical College Hospital
Phase 2
Completed
62 enrolled